Evidence map›Paper›PMID 30541475›Full record

ArticleBMC medical research methodology2018

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.

Victoria J Serpas, Kanwal P Raghav, Daniel M Halperin, James Yao, Michael J Overman

Abstract read
In one paragraph

Article in BMC medical research methodology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victoria J SerpasInternal Medicine Residency Program, Baylor College of Medicine/ The University of Texas MD Anderson Cancer Center, 1 Baylor Plaza, Houston, TX, 77030, USA.
Kanwal P RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA.
Daniel M HalperinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA.
James YaoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA.
Michael J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson, 1515 Holcombe Blvd, Unit 426, Houston, TX, 77030, USA. moverman@mdanderson.org.ORCID 0000-0001-5377-135X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials are an essential part of evidence-based medicine. Hence, to ensure transparency and accountability in these clinical trials, policies for registration have been framed with emphasis on mandatory submission of trial elements, specifically outcome measures. As these efforts evolve further, we sought to evaluate the current status of endpoint reporting in clinical trial registries.

methodsWe reviewed 71 oncology related randomized controlled trials published in three high impact journals. We compared primary (PEP) and non-primary endpoints (NPEP) between the clinical trial protocols of these trials and their corresponding registration in one of the 14 primary global clinical trial registries. A discrepancy was defined as the non-reporting or absence of an endpoint in either the protocol or registry. The primary endpoint was the rate of discrepancy between secondary endpoints in clinical trial protocols and clinical trial registries.

resultsOf the 71 clinical trials, a discrepancy in PEP was found in only 4 trials (6%). Secondary endpoint (SEP) differences were found in 45 (63%) trials. Among these 45 trials, 36 (80%) had SEPs that were planned in the protocol but not reported in the registry and 19 (42%) had SEPs with endpoints in the registry that were not found in the protocol. The total number of SEPs that were absent from the corresponding registry and protocol were 84 and 29, respectively. Of these endpoints, 48 (57%) and 9 (31%) were included in the published report of these trials.

conclusionAlthough recent regulations and enhanced procedures have improved the number and quality of clinical trial registrations, inconsistencies regarding endpoint reporting still exist. Though further guidelines for the registration of clinical trials will help, greater efforts to provide a correct, easily accessible, and complete representation of planned endpoints are needed.

Indexed as

Data AccuracyEndpoint DeterminationEvidence-Based MedicineHumansMedical OncologyOutcome Assessment, Health CarePublicationsRandomized Controlled Trials as TopicRegistriesResearch ReportEndpointsRegistryReporting

Identifiers

PMID30541475
PMCPMC6292048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.